 BOSTON, Jan. 05, 2021 GLOBE NEWSWIRE -- Radius Health, Inc. Radius or the Company Nasdaq: RDUS today announced that the Company has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc Endo NASDAQ: ENDP, to register, commercialize, and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc. Paladin, an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the terms of the agreements, Paladin will pay Radius upfront and milestone payments up to approximately 8.0 million and tiered royalties up to the mid-twenties on net sales in Canada. 